206 related articles for article (PubMed ID: 29104622)
1. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.
Liu Y; Zhang Y; Feng G; Niu Q; Xu S; Yan Y; Li S; Jing M
Exp Ther Med; 2017 Nov; 14(5):4017-4032. PubMed ID: 29104622
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
Li D; Yao L; Xu L; Li W; Che Y
Medicine (Baltimore); 2022 Dec; 101(48):e32164. PubMed ID: 36482605
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Liu GF; Li XF; Yu SN; Miao YY; Zhang SH
J Cell Physiol; 2019 Apr; 234(4):3445-3457. PubMed ID: 30374969
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
BMC Cancer; 2018 Aug; 18(1):780. PubMed ID: 30068310
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Zhang W; Wei Y; Yu D; Xu J; Peng J
Medicine (Baltimore); 2018 Apr; 97(16):e0460. PubMed ID: 29668619
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
11. Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.
He Q; Liu J; Cai X; He M; Li C; Liang H; Cheng B; Xia X; Guo M; Liang P; Zhong R; Li F; Yu Z; Zhao Y; Ou L; Xiong S; Li J; Zhang J; He J; Liang W
Transl Lung Cancer Res; 2021 Nov; 10(11):4120-4129. PubMed ID: 35004243
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model.
Tan J; Li M; Zhong W; Hu C; Gu Q; Xie Y
Oncotarget; 2017 Nov; 8(58):98771-98781. PubMed ID: 29228726
[TBL] [Abstract][Full Text] [Related]
14. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
15. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Kaira K; Naito T; Takahashi T; Ayabe E; Shimoyama R; Kaira R; Ono A; Igawa S; Shukuya T; Murakami H; Tsuya A; Nakamura Y; Endo M; Yamamoto N
Lung Cancer; 2010 Apr; 68(1):99-104. PubMed ID: 19540616
[TBL] [Abstract][Full Text] [Related]
18. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Song ZB; Yu YF; Chen ZW; Lu S
Chin Med J (Engl); 2011 Aug; 124(15):2279-83. PubMed ID: 21933557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
